Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
The Journal of Organic Chemistry|June 26, 1996
Different Pathways in the Base-Promoted Isomerization of Benzyl Oxiranyl EthersAlessandro Mordini, Simona Bindi, Sabina Pecchi, et al.Bioorganic & Medicinal Chemistry Letters|November 2, 2010
Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitorsSabina Pecchi, Paul A Renhowe, Clarke Taylor, et al.Bioorganic & Medicinal Chemistry Letters|July 4, 2013
Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3KSabina Pecchi, Zhi-Jie Ni, Wooseok Han, et al.Bioorganic & Medicinal Chemistry Letters|February 1, 2006
Design and structure-activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinasesKelly Frazier, Elisa Jazan, Christopher M McBride, et al.Bioorganic & Medicinal Chemistry Letters|April 11, 2006
4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK-1 inhibitorsZhi-Jie Ni, Paul Barsanti, Nathan Brammeier, et al.Bioorganic & Medicinal Chemistry Letters|January 18, 2016
Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft modelWooseok Han, Daniel L Menezes, Yongjin Xu, et al.ACS Medicinal Chemistry Letters|June 6, 2014
Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase InhibitorsMatthew T Burger, Mark Knapp, Allan Wagman, et al.ACS Medicinal Chemistry Letters|July 21, 2015
Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 InhibitorAlexei S Karpov, Payman Amiri, Cornelia Bellamacina, et al.Molecular Cancer Therapeutics|December 23, 2011
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitorSauveur-Michel Maira, Sabina Pecchi, Alan Huang, et al.Journal of Medicinal Chemistry|December 31, 2008
Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitorsPaul A Renhowe, Sabina Pecchi, Cynthia M Shafer, et al.Pageof 2